Results 181 to 190 of about 1,044,683 (223)
Safety and efficacy evaluation of albumin-bound paclitaxel
Expert Opinion on Drug Safety, 2014 Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel, which was developed to avoid toxicities associated with Cremophor EL® vehicle used in solvent-based paclitaxel. It is approved as monotherapy for treatment of metastatic breast cancer (MBC) in Europe and the US; in combination therapy for non-small-
Paolo Baldo +2 more
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Albumin-bound paclitaxel: a next-generation taxane
Expert Opinion on Pharmacotherapy, 2006Taxanes are standard treatment for metastatic breast cancer; however, the solvents used as vehicles in these formulations cause severe toxicities. The FDA recently approved a solvent-free formulation of paclitaxel for the treatment of metastatic breast cancer that utilises 130-nanometer albumin-bound (nab) technology (Abraxane; nab-paclitaxel) to ...
exaly +3 more sources
Drugs, 2006
A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distribution volume and greater clearance ...
Dean M, Robinson, Gillian M, Keating
openaire +2 more sources
A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distribution volume and greater clearance ...
Dean M, Robinson, Gillian M, Keating
openaire +2 more sources
Liposomal Paclitaxel and Albumin-bound Paclitaxel (Nanovehicle Agents) for Gastric Cancer
Journal of Modern Nanotechnology, 2023Gastric cancer has the third-highest cancer-related mortality rate. Paclitaxel is a microtubule stabilizer whose systemic chemotherapy regimen is widely used in clinical practice due to its major role in the chemotherapy of advanced gastric cancer.
Minghua Liu, Na Gao, Xueqing Wang
openaire +1 more source
Nanomedicine, 2022
Aim: The present study aimed to retrospectively compare the efficacy and safety between liposomal paclitaxel (Lps-P) and nanoparticle albumin-bound paclitaxel (Nab-P) in neoadjuvant systemic treatment (NST) of breast cancer. Materials & methods: Two hundred thirty-five patients who were diagnosed with invasive breast cancer and then received dose-dense
Weiwei Zhang +12 more
openaire +2 more sources
Aim: The present study aimed to retrospectively compare the efficacy and safety between liposomal paclitaxel (Lps-P) and nanoparticle albumin-bound paclitaxel (Nab-P) in neoadjuvant systemic treatment (NST) of breast cancer. Materials & methods: Two hundred thirty-five patients who were diagnosed with invasive breast cancer and then received dose-dense
Weiwei Zhang +12 more
openaire +2 more sources
Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer
Journal of Clinical Oncology, 20071101 Background: Miller, et al demonstrated the combination of bevacizumab and paclitaxel has significant activity in metastatic breast cancer. Because paclitaxel albumin bound (PAB) has been shown to have less toxicity, a better tumor delivery and possibly better response for metastatic breast cancer, we combined it with bevacizumab (B) to treat ...
John S, Link +3 more
openaire +2 more sources
Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer
Drugs of Today, 2006Two taxanes, paclitaxel and docetaxel, are among the most widely used chemotherapeutic agents in solid tumor oncology, with efficacy against tumors of the breast, lung, head and neck, ovary, prostate, stomach and urothelium. The taxanes have been studied extensively and have been proven effective for treating early and advanced breast cancer.
Mary C, Pinder, Nuhad K, Ibrahim
openaire +2 more sources
Nanoparticle Albumin–Bound Paclitaxel for Metastatic Breast Cancer
Journal of Clinical Oncology, 2005The taxanes, paclitaxel and docetaxel, are among the most important drugs in the modern treatment of metastatic breast cancer. By the mid 1990s, several phase II trials had demonstrated both agents to have considerable activity in the metastatic setting.
Harries, M, Ellis, P, Harper, P
openaire +2 more sources
Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer
Drugs, 2015Nanoparticle albumin-bound paclitaxel (Abraxane) [hereafter referred to as nab-paclitaxel] is a taxane developed to avoid some of the toxicities associated with solvent-bound (sb) paclitaxel. Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not ...
Hannah A, Blair, Emma D, Deeks
openaire +2 more sources
Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer
Journal of Oncology Pharmacy Practice, 2008Background. An albumin-bound formulation of paclitaxel (nab-paclitaxel) was developed to provide additional efficacy and to overcome the safety drawbacks of paclitaxel and docetaxel in patients with metastatic breast cancer. To provide health economic data for the Canadian setting, an economic analysis comparing each of nab-paclitaxel and docetaxel ...
George, Dranitsaris +3 more
openaire +2 more sources